MedTrace Logo

Extension, Carbidopa-levodopa in Neovascular Age-related Macular Degeneration (AMD)

NCT03197493 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-09-12

Study results available
· View outcomes & findings →

Summary

This protocol is an extension of protocol 0002, Proof of Concept and Dose Ranging Study of carbidopa-levodopa in Neovascular AMD. that is a 3 month study of escalating doses of carbidopa-levodopa in neovascular AMD. This trial is a 9 month extension for patients who successfully complete protocol 0002 and wish to continue carbidopa-levodopa therapy. It will use the two higher dose regimens of protocol 0002. these will be assigned according to how well the higher dose was tolerated in protocol 0002.

Conditions

  • Macula; Degeneration
  • Retina

Interventions

DRUG

carbidopa-levodopa 25-100 mg

High Dose: daily oral administration 2 tablets TID Intermediate Dose: daily oral administration 1 tablet TID

Sponsors & Collaborators

  • Snyder Biomedical Corporation

    collaborator OTHER

  • Snyder, Robert W., M.D., Ph.D., P.C.

    lead INDIV

Principal Investigators

  • Robert W Snyder, MD, PhD · Robert W Snyder

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2020-07-09
Completion
2020-07-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03197493 on ClinicalTrials.gov